Premium
MDMA‐assisted psychotherapy reduces PTSD symptom severity
Author(s) -
Canady Valerie A.
Publication year - 2021
Publication title -
mental health weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7583
pISSN - 1058-1103
DOI - 10.1002/mhw.32682
Subject(s) - mdma , psychiatry , psychology , hallucinogen , posttraumatic stress , psychotherapist , medicine , clinical psychology
Prior use of selective serotonin reuptake inhibitors (SSRIs) may reduce the effectiveness of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted therapy for post‐traumatic stress disorder (PTSD), say researchers of a recent study who noted that MDMA is close to being considered the first psychedelic drug approved to treat PTSD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom